Metamizol Stada (Metamizole Sodium Monohydrate)

Metamizole works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production. This action reduces peripheral inflammation and also provides central analgesic effects by modulating spinal pain pathways, resulting in both pain relief and fever reduction.

The appropriate dose of Metamizol Stada is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Dosing instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for metamizole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole belongs to the pyrazolone class, offering strong analgesic and antipyretic effects similar to non‑steroidal anti‑inflammatory drugs (NSAIDs) but with a different safety profile. Unlike many NSAIDs, it has a lower risk of gastrointestinal irritation but carries a rare risk of severe blood disorders such as agranulocytosis.

Metamizol Stada should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain its stability and potency.

Metamizol Stada is supplied as an oral dosage form and is taken by mouth with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water; it should not be crushed or chewed unless specifically instructed.

The most serious adverse reactions include agranulocytosis, aplastic anemia, severe skin reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should be monitored for signs of infection, unexplained fever, rash, or breathing difficulties, and seek immediate medical attention if these occur.

Metamizol Stada should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, in patients with a history of severe blood dyscrasias, and in those currently receiving other myelosuppressive therapies unless closely supervised by a physician.